| Dr Alfredo L Blas Iii, MD | |
|
700 High St, Williamsport, PA 17701-3198 | |
| (570) 321-2850 | |
| (570) 321-2851 |
| Full Name | Dr Alfredo L Blas Iii |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 27 Years |
| Location | 700 High St, Williamsport, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063412948 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD428162 (Pennsylvania) | Secondary |
| 208M00000X | Hospitalist | MD428162 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Williamsport Regional Medical Center | Williamsport, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Susquehanna Physician Services | 2264336460 | 492 |
News Archive
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Neutra Corp., a provider of all-natural wellness solutions, announced today that its wholly owned subsidiary, Diamond Anvil Designs, is preparing to release its cutting-edge new vaporizer pen next month.
"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).
The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.
› Verified 6 days ago
| Entity Name | Susquehanna Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992743868 PECOS PAC ID: 2264336460 Enrollment ID: O20040412001371 |
News Archive
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Neutra Corp., a provider of all-natural wellness solutions, announced today that its wholly owned subsidiary, Diamond Anvil Designs, is preparing to release its cutting-edge new vaporizer pen next month.
"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).
The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alfredo L Blas Iii, MD 1201 Grampian Blvd, Williamsport, PA 17701-1900 Ph: () - | Dr Alfredo L Blas Iii, MD 700 High St, Williamsport, PA 17701-3198 Ph: (570) 321-2850 |
News Archive
Savient Pharmaceuticals, Inc. announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for KRYSTEXXA™ (pegloticase) as a treatment for chronic gout in patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.
Neutra Corp., a provider of all-natural wellness solutions, announced today that its wholly owned subsidiary, Diamond Anvil Designs, is preparing to release its cutting-edge new vaporizer pen next month.
"Ohioans with pre-existing health conditions, such as cancer or diabetes, can apply for coverage under a new high-risk insurance pool beginning Aug. 1." Qualifications include evidence of a pre-existing condition, proof of Ohio residency and U.S. citizenship, state of being uninsured for six months prior to the date of applying for coverage and being "ineligible for coverage under the Medicare program, the Ohio Medical Assistance Program, the Ohio Children's Health Insurance Program, or an employer-sponsored group health plan, unless subject to a mandatory initial waiting period" (7/22).
The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.
› Verified 6 days ago
Asif Javed, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 | |
Dr. Lalita Mittal, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 Fax: 570-321-2851 | |
Fahmi Rahman, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 | |
Puneet Gupta, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 Fax: 570-321-2851 | |
Dr. Mohammad Mahmoud Alkhawaja, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 | |
Harry Rose, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-2850 | |
Paul Chiarulli, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 700 High St, Williamsport, PA 17701 Phone: 570-321-1000 |